It was completely life-changing. I could function.
Across Britain, pregnant women suffering from hyperemesis gravidarum — a severe and debilitating form of pregnancy sickness — face unequal access to Xonvea, the only drug with specific regulatory approval for their condition. Though the NHS has sanctioned the medication, local health boards weigh its £28 cost against cheaper alternatives, making geography rather than clinical need the deciding factor in who receives effective treatment. This postcode lottery reflects a broader tension within publicly funded healthcare: how a system of finite resources reconciles the principle of equal care with the reality of unequal distribution.
- Women with hyperemesis gravidarum are vomiting up to ten times a day, unable to eat, and in some cases resorting to physical self-distraction just to endure the relentless nausea.
- Xonvea — the only MHRA-approved drug specifically for pregnancy sickness — is being withheld from many patients not because it is unsafe or ineffective, but because it costs roughly seven times more than older alternatives.
- Bureaucratic barriers compound the suffering: some women spend weeks chasing consultant approvals, only to find that a four-minute private GP appointment unlocks the prescription the NHS had denied them.
- Access is determined by which Integrated Care Board a woman lives under, creating a system where the same condition receives meaningfully different treatment depending on postcode.
- The NHS has acknowledged the inequity and is working toward a Single National Formulary, but advocates and patients warn that a future promise offers no relief to women who are suffering today.
Linzi Kinghorn's experience with hyperemesis gravidarum — a severe pregnancy condition involving relentless nausea and vomiting — led her to a troubling discovery: not every woman in Britain could access the same NHS-approved medication that had helped her recover.
Jasmeen Basi, a mother of three from Southampton, lived that inequality firsthand. During her pregnancies she vomited up to ten times a day and at her lowest point was hitting her head against walls to distract herself from the nausea. Standard first-line treatments barely helped. By her third pregnancy she knew she needed Xonvea, but her GP couldn't prescribe it without consultant approval — a process that stalled for weeks. Desperate, she paid for a private appointment. Within four minutes she had a prescription. Within days, she could function again.
Xonvea holds a distinction no other pregnancy sickness drug can claim: it is the only medication with specific MHRA regulatory approval for nausea, vomiting, and hyperemesis in pregnancy. Yet it is not routinely offered on the NHS. The obstacle is cost — roughly £28 per packet compared to £3 or £4 for older antihistamine alternatives. Professor Catherine Nelson-Piercy, who helped shape national guidance on hyperemesis, notes that Xonvea is equally safe and effective as cheaper options, but cost rather than clinical evidence frequently determines what a woman receives.
Whether a patient can access Xonvea depends largely on where she lives. Some Integrated Care Boards have added it to their approved formularies, though often only for women who have already failed other treatments. Elsewhere it may not appear at all. Marianne Eldridge of the Pregnancy Sickness Support charity describes it plainly as a postcode lottery — her organisation's surveys show the overwhelming majority of women who tried Xonvea found it more effective than alternatives, yet access remains a matter of geography and local bureaucracy rather than medical need.
The NHS has acknowledged the problem. A Department of Health spokesperson confirmed that work is underway toward a Single National Formulary intended to standardise access across the country. But for women vomiting repeatedly and unable to eat today, that remains a distant promise — and the question of whether a postcode should determine access to a proven, approved treatment remains unanswered.
Linzi Kinghorn was pregnant and severely ill. The sickness wasn't the mild queasiness most women experience in early pregnancy—it was relentless, debilitating, the kind that kept her in bed and made eating nearly impossible. When her GP diagnosed her with Hyperemesis Gravidarum, a serious condition marked by extreme nausea and vomiting during pregnancy, Kinghorn learned there were treatment options available on the NHS. One of them, a drug called Xonvea, worked for her quickly and well. But as she investigated further, she discovered something troubling: not every pregnant woman in Britain could access the same medication, even though it was approved by the health service.
Jasmeen Basi, a mother of three from Southampton, knows this struggle intimately. During her pregnancies, she experienced hyperemesis so severe that she vomited ten times a day, couldn't keep food down, and at one point was hitting her head against walls just to get temporary relief from the nausea. Her GP offered her standard first-line treatments—drugs that cost three or four pounds per packet—but they barely touched her symptoms. She was still vomiting six times daily. By her third pregnancy, Basi had done her research and knew what she needed. She called her GP as soon as she got a positive test result, asking specifically for Xonvea. What followed was a bureaucratic maze. Her GP couldn't prescribe it directly; approval had to come from a consultant. Basi spent weeks on the phone chasing the paperwork, getting nowhere. Finally, desperate and exhausted, she paid for a private GP appointment. Within four minutes of that consultation, she had a prescription in her inbox. Within days, her life changed. She could function again.
Xonvea is unique among pregnancy sickness medications. It's the only one that carries specific regulatory approval from the Medicines and Healthcare products Regulatory Authority for treating nausea, vomiting, and hyperemesis in pregnancy. The MHRA has reviewed the evidence, confirmed its safety and effectiveness. Yet it is not always the first drug offered to pregnant women on the NHS. The reason is cost. Xonvea costs about £28 per packet. The older antihistamine alternatives cost £3 or £4. In a health system managing finite budgets, that difference matters. Professor Catherine Nelson-Piercy, who helped develop national guidance for managing hyperemesis, explains that while Xonvea is equally safe and effective as the cheaper options, it sits alongside them as a first-line choice, not above them. Cost, not clinical evidence, often determines which drug a woman receives.
Whether a pregnant woman can actually get Xonvea depends on where she lives. In Hampshire and the Isle of Wight, the local Integrated Care Board has included it on the official list of approved medications. But even there, access comes with conditions. The drug is reserved for women who haven't responded to other treatments or can't tolerate them. In other parts of the country, it may not be on the formulary at all. Marianne Eldridge, from the Pregnancy Sickness Support charity, calls it a postcode lottery. Her organization surveyed women who had taken Xonvea and found the vast majority found it more effective than other medications they'd tried. Yet access remains inconsistent, dependent not on medical need but on geography and local bureaucracy.
The NHS is aware of the problem. A Department of Health and Social Care spokesperson acknowledged that decisions about prescribing are made by individual doctors, and that work is underway to move toward a Single National Formulary designed to improve equitable access across the country. Neil Hardy, Chief Pharmacist for NHS Hampshire and Isle of Wight, noted that the organization welcomes this shift toward consistency. But for women suffering now—vomiting repeatedly, unable to eat, desperate for relief—consistency remains a future promise. Basi's experience illustrates the gap between what the NHS approves and what it actually delivers. A drug proven safe and effective, available on the health service, yet accessible only to some, and only after a fight. The question facing the NHS is whether a woman's postcode should determine whether she gets the medication that works.
Notable Quotes
Getting hold of Xonvea in the UK at the moment is really difficult. It's a postcode lottery drug.— Marianne Eldridge, Pregnancy Sickness Support charity
Xonvea is the only one that has a specific label for use to treat nausea, vomiting and hyperemesis. Because of the different costs, it is actually unlikely to be the drug she's offered first.— Professor Catherine Nelson-Piercy, Obstetric Medicine
The Hearth Conversation Another angle on the story
Why does cost matter so much if Xonvea is genuinely more effective?
It's not that it's more effective—it's equally effective as the cheaper drugs. But it costs seven times more. In a system with fixed budgets, that's the deciding factor. The cheaper drugs work for many women, so from a pure economics standpoint, they're prescribed first.
But Jasmeen Basi's story shows the cheaper drugs didn't work for her.
Exactly. That's the cruelty of it. Some women respond to the cheaper options. Others don't. But the system doesn't account for individual variation—it just defaults to cost. Basi had to go private to get what she needed in days.
Why isn't this a national standard if it's NHS-approved?
Because the NHS doesn't work as one unified system. Each local health board decides its own formulary. Hampshire includes Xonvea; other areas don't. It's fragmented by design, which means two pregnant women with identical symptoms get different care depending on their postcode.
What's the actual barrier—is it the drug companies, the regulators, or the NHS itself?
All three, in different ways. The regulators approved it. The drug companies price it high. The NHS, facing budget constraints, uses cost as the tiebreaker. No one is acting unreasonably in isolation, but the system produces an unreasonable outcome.
Is there any movement toward fixing this?
Yes, but it's slow. The NHS is working toward a Single National Formulary that would standardize access. But that's future work. Right now, women are suffering and paying privately for what should be equally available to everyone.